RAF inhibition and induction of cutaneous squamous cell carcinoma

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Targeted anticancer therapies, particularly kinase inhibitors, are frequently associated with dermatological side effects.
• Several kinase inhibitors have been linked to the development of benign and malignant skin tumors, including keratoacanthomas and squamous cell carcinomas.

Discussion:

• This review explores the mechanisms underlying RAF inhibitor-induced skin neoplasms.
• It examines the clinical management and broader implications of these unexpected cutaneous toxicities.

Key Insights:

• Emerging evidence indicates that RAF inhibition is a primary driver of these skin neoplasms.
• More potent and specific RAF inhibitors are associated with a higher frequency and earlier onset of these tumors compared to less specific agents like sorafenib.
• RAF inhibition can lead to paradoxical activation of the MAPK signaling pathway in cells lacking BRAF mutations, contributing to tumor development.

Outlook:

• Understanding the mechanisms of RAF inhibition-induced skin tumors is crucial for clinical practice.
• Further research aims to elucidate these pathways to develop strategies for preventing skin tumor initiation during anticancer therapy.
• Findings will inform future drug development for targeted anticancer agents with improved safety profiles.